Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
There May Still Be Time to Get in on These 3 Trending Biotechs Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
SpringWorks Therapeutics Stock Gets A RS Rating Lift The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Arcellx Stock Earns 82 Relative Strength Rating Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
BioNTech Stock Got A IBD RS Rating Lift A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Vericel Stock Sees RS Rating Shoot Higher The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Buckle Up And Use Volitility To Your Advantage The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary.
What You Missed On Wall Street This Past Friday Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
